Back

Cost-effectiveness of Sacubitril/Valsartan in acute and chronic heart failure with reduced ejection fraction: from randomized controlled trials to real-world evidence

22 May 2023 (10:36 - 12:12)
Organised by: Logo
Congress Presentation Part of: ePosters in acute heart failure 7 Pharmacotherapy HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Yu-Min Lin

Chi-Mei Medical Center, Tainan (Taiwan)

4 More presentations in this session

Presentation thumbnail
Clinical presentation, shock severity and mortality in patients with de novo vs. acute-on-chronic heart failure-related cardiogenic shock
Doctor J. Sundermeyer (Hamburg, DE)
Abstract Slides
Presentation thumbnail
Analysis of the implantation of heart failure with reduced ejection fraction treatment in clinical practice and its impact on achieving target doses
Doctor A. Esteban Fernandez (Leganes, ES)
Abstract Slides
Presentation thumbnail
Role of specialised heart failure unit in optimisation of guideline-directed medical therapy - real world data
Doctor E. Macken (London, GB)
Abstract Slides
Presentation thumbnail
Diabetes predicts in-hospital outcomes in men but not in women with acute myocardial infarction
Doctor A. Poniku (Pristina, XK)
Abstract Slides

Access the full session

Session thumbnail
ePosters in acute heart failure 7

The Event

Event poster

Heart Failure 2023

22 May 2023 10:36 CET
You may be interested in
thumbnail
Congress Session
Acute heart failure therapies: from clinical trials to clinical practice
thumbnail
Congress Session
Devices in acute heart failure
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources